Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 20:11:1999.
doi: 10.3389/fmicb.2020.01999. eCollection 2020.

Mumps Vaccines: Current Challenges and Future Prospects

Iman Almansour  1
Affiliations
Review

Mumps Vaccines: Current Challenges and Future Prospects

Iman Almansour. Front Microbiol. .

Abstract

Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the rise, including in populations with high vaccination coverage. Several epidemiological studies suggest that this infectious virus continues to be a worldwide public health threat. The development and deployment of an improved, prophylactic mumps vaccine that provides long-lasting protection is indeed a priority. The purpose of this review is to provide an immuno-biological perspective on mumps vaccines. Here, we review the virology of mumps, licensed mumps vaccines, and the typical immune responses elicited following mumps vaccination. Furthermore, we discuss the limitations and challenges of the currently licensed mumps vaccines and provide strategies for the development of an improved mumps vaccine.

Keywords: MMR; hemagglutinin-neuraminidase; immunity; mumps; safety; vaccine; vaccine efficacy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abrams S., Beutels P., Hens N. (2014). Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data. Am. J. Epidemiol. 179, 1006–1017. 10.1093/aje/kwu014, PMID: - DOI - PubMed
    1. Almansour I., Alfares R., Aljofi H. (2018). Large-scale analysis of B-cell epitopes of envelope: implications for Zika vaccine and immunotherapeutic development. F1000Res. 7:1624. 10.12688/f1000research.16454.1, PMID: - DOI - PMC - PubMed
    1. Almansour I., Alhagri M. (2019). MMRdb: measles, mumps, and rubella viruses database and analysis resource. Infect. Genet. Evol. 75:103982. 10.1016/j.meegid.2019.103982, PMID: - DOI - PubMed
    1. Béraud G., Abrams S., Beutels P., Dervaux B., Hens N. (2018). Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. Euro Surveill. 23:1700796. 10.2807/1560-7917.ES.2018.23.25.1700796, PMID: - DOI - PMC - PubMed
    1. Brown E. G., Dimock K., Wright K. E. (1996). The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J. Infect. Dis. 174, 619–622. 10.1093/infdis/174.3.619, PMID: - DOI - PubMed

LinkOut - more resources